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Cost-effectiveness of Spa treatment for fibromyalgia: general health
improvement is not for free
T. R. Zijlstra1,3, L. M. A. Braakman-Jansen2, E. Taal2, J. J. Rasker2 and M. A. F. J. van de Laar1,2
Objectives. To estimate the cost-effectiveness of an adjuvant treatment course of spa treatment compared with usual care only in patients
with fibromyalgia syndrome (FM).
Methods. 134 patients with FM, selected from a rheumatology outpatient department and from members of the Dutch FM patient association
were randomly assigned to a 2½ week spa treatment course in Tunisia or to usual care only. Results are expressed as quality-adjusted life
years (QALYs) for a 6-month as well as a 12-month time horizon. Utilities were derived form the Short Form 6D (SF-6D) scores and the visual
analogue scale (VAS) rating general health. Costs were reported from societal perspective. Mean incremental cost per patient and the
incremental cost utility ratio (ICER) were calculated; 95% confidence intervals (CIs) were estimated using double-sided bootstrapping.
Results. The data of 128 (55 spa and 73 controls) of the 134 patients (96%) could be used for analysis. Improvement in general health
was found in the spa group until 6 months of follow-up by both the SF-6D (AUC 0.32 vs 0.30, P< 0.05) and the VAS (AUC 0.23 vs 0.19,
P< 0.01). After 1yr no significant between-group differences were found. Mean incremental cost of spa treatment was E1311 per patient
(95% CI 369–2439), equalling the cost of the intervention (thalassotherapy including airfare and lodging), or E885 per patient based on
a more realistic cost estimate.
Conclusions. The temporary improvement in quality of life due to an adjuvant treatment course of spa therapy for patients with FM is
associated with limited incremental costs per patient.
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Introduction
Fibromyalgia (FM) is a syndrome characterized by chronic
widespread musculoskeletal pain and increased tenderness to
palpation [1]. Although the exact cause of FM is unknown, it is
suggested that a combination of biological, psychological and
social factors leads to pain amplification and central sensitization
to peripheral stimuli [2]. Pain and other important features
like sleep disturbance and fatigue all contribute to increasing
disability and reduced quality of life [3]. Furthermore, FM is
associated with increased health care consumption, significant
productivity loss and considerable economic costs [4–6].
Until now, treatment results in FM are mostly unsatisfactory.
Several forms and combinations of physical exercise and patient
education have been shown to have positive effects, but effect sizes
are often moderate, drop-out rates considerable and long-term
effects unknown [6, 7].
In this century, health care policy will increasingly be based
on cost–benefit ratios of new interventions. However, cost-
effectiveness of treatment programmes for FM has not been
subject to study up till now [7]. In a previous publication, we
concluded that a group programme of thalassotherapy, exercise
and patient education (spa treatment) resulted in temporary
improvement of FM symptoms and health-related quality of
life [8]. This article addresses the health economic aspects of spa
treatment compared with usual care in patients with FM. The




The pre-randomized controlled clinical trial (RCT) has been
described previously [8]. Outcome assessments were done at
baseline and after 1, 3, 6 and 12 months. Costs were measured
prospectively via monthly questionnaires filled out by the patients.
In order to test group differences for costs at baseline, retro-
spective data about health care consumption and employment
status over the past 6 months were collected as well. The study was
approved by the Medical Ethical Committee of Medisch Spectrum
Twente Hospital, Enschede, The Netherlands. All participants
gave written informed consent.
Patients
Patients with primary FM were included if they met the following
criteria: a diagnosis of primary FM made by a rheumatologist,
according to the ACR 1990 classification criteria [1]; age between
18 and 65 years; willingness to undergo an in-patient treatment
of some weeks. Exclusion criteria were: secondary FM; comor-
bidity interfering with spa treatment; other serious comorbidity;
dependency on a wheelchair or help from other people; current
involvement in a legal procedure concerning disability or employ-
ment; recent spa treatment for musculoskeletal disorders;
difficulty understanding Dutch.
Intervention
The Spa treatment (SPA) was given on the Island of Jerba,
Tunisia. Three groups of up to 20 patients travelled to Jerba by air
and stayed in a luxurious tourist hotel on a full-board basis for
2½ weeks, sharing rooms with a fellow patient. The treatment
programme consisted of five elements: thalassotherapy, group
exercise, patient education, recreational activities and relaxation.
Thalassotherapy was provided in a thalasso centre by
qualified Tunisian staff. It consisted of seven 3 h sessions. The
supervised group exercise (max. five patients per group) included
seven 1 h sessions with various forms of low-impact aerobic
exercise. The patient education programme consisted of seven
sessions in groups of up to 10 patients, directed by the
1Medisch Spectrum Twente Hospital, Department of Rheumatology, Enschede,
2University Twente, Faculty of Behavioural Sciences, Department of Psychology
and Communication of Health and Risk (PCHR), Enschede and 3Isala Klinieken,
Department of Rheumatology, Zwolle, The Netherlands.
Submitted 16 February 2007; revised version accepted 4 May 2007.
Correspondence to: L. M. A. Braakman-Jansen, PhD, University of Twente,
Institute for behavioural Research, Department of Psychology and Communication
of Health and Risk (PCHR), PO BOX 217, 7500 AE Enschede, The Netherlands.
E-mail: l.m.a.braakman-jansen@gw.utwente.nl
Rheumatology 2007;46:1454–1459 doi:10.1093/rheumatology/kem157
Advance Access publication 17 July 2007
1454
 The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org







rheumatologist (T.R.Z.). Details of the intervention have been
published before [8]. In the control group, patients continued to
receive their usual care (UC) only.
Utility measurement
Utilities refer to preferences individuals or society may have for
any particular health state [9] and value the health of the patient
from 0 (as bad as death) to 1 (perfect health). For the present
study, utilities were assessed in two different ways, using the
RAND-36 and a visual analogue scale (VAS) for general health.
The RAND-36 [a validated Dutch version of the Short Form
(SF)-36 health survey] measures general health status [10]. From
the RAND-36, the SF-6D utility index was calculated [11].
The SF-6D reflects the general public’s valuation of health states
derived from the SF-36. General health was also measured with
a 100mm VAS. The VAS score ranges from 0 to 100: worst
imaginable to best imaginable health.
Costs
Societal costs during the 1 yr follow-up period were assessed
and valued in accordance to the Dutch guidelines for pharmaco-
economic research [12] including direct and indirect medical costs
as well as indirect non-medical costs. Both FM-related and other
costs were included, since it is sometimes difficult to distinguish
one from the other.
Table 1 lists all direct and indirect costs that were included in
the analysis, presenting the method of valuation, the cost price per
unit and its source. Most cost prices were obtained from Dutch
standard prices as described in the Dutch manual for costing
by Oostenbrink et al. [13]. This manual was designed to increase
standardization in costing methodology among studies. Prices of
1999 as stated in the cost manual of Oostenbrink et al. [13] were
converted to the price level of the year 2000 using the price index
rate for the Dutch health care sector of 2.6% (obtained from
Statistics Netherlands).
The cost of the spa treatment programme was based on
the costs of thalassotherapy, travel expenditures, accommodation
and overhead costs including staff expenses. Total costs were
estimated at E1526 per patient. A second calculation was made
in which package deals because of group discount and 2007
airfares were taken into account. This way the total costs of spa
treatment were estimated at E1125. Both prices were applied in
the analysis.
Absenteeism from work was calculated by using the friction
cost method. This method is based on the idea that the amount of
production lost due to disease depends on the time span employers
need to restore the initial production level. Hence, this method
assumes that production losses are confined to the period needed
to replace a sick worker. This ‘friction period’ is limited to a
maximum of 123 days [13, 14]. Domestic help was classified into
three categories. Professional domestic care (provided by profes-
sional home care organizations and reimbursed by health
insurance), paid household help (privately paid, not reimbursed)
and informal care (unpaid help from relatives or friends).
Informal care was limited to a maximum of 28 h/week.
Statistical analysis
Results are expressed as quality-adjusted life years (QALYs).
QALYs are an accepted measure for resource allocation decisions
involving different treatments and patient populations. A QALY
is a composite index that includes effects in terms of both quality
of life (utility) and the duration of time in such a health state [9].
Therefore, the time-integrated summary score, the area under the
curve (AUC) of the utilities, was calculated to define the quality of
life per period (0–6 months and 0–1 yr), based on the assumption
that utilities followed a linear course over time between the
assessments. Between-group differences in QALYs were analysed
per period by Student’s t-test for unpaired observations.
The costs are presented as arithmetic means (S.D.) per patient
per group. The between-group differences in resource use were
analysed per period by Mann–Whitney U-test. Mean incremental
costs per patient and study period were calculated and 95% CI
were estimated using double-sided bootstrapping.
The incremental cost utility ratio (ICER) was calculated by
dividing the extra costs for the intervention group by the extra
QALYs derived from it. The ICER is expressed as costs per
QALY gained. The 95% CIs of the ratios were estimated with
bootstrapping. Costs and effects were not discounted as the
time horizon of this study was less than 1 yr and no modelling
beyond the observed period was done.
Results
Data from 128 of the 134 patients (96%) could be used
for analysis (55 SPA and 73 UC). The excluded patients (three
from SPA and three from UC-group) completed <50% of the
cost diaries. However, they did not differ from the study group
TABLE 1. Categories, methods and sources for valuation of unit costs
Cost categories Unit of resource Source of the estimate Cost per unit E
Medical costs
Spa treatmenta Total costs Study registration E1526
General practitioner Number of visits Cost manual of Oostenbrink et al. [13] E17.05
Specialist Number of visits Cost manual of Oostenbrink et al. [13] E50.05
Paramedical professionals Number of visits Cost manual of Oostenbrink et al. [13] E18.90
Alternative medicine Total costs Patient-reported cost
Hospitalization
General hospital Days admitted Cost manual of Oostenbrink et al. [13] E243
University hospital Days admitted Cost manual of Oostenbrink et al. [13] E341
Prescription drugs Kind and number of prescriptions Pharmacotherapeutic Compass 2000 [24]
Over-the-counter (OTC) drugs Kind and total costs Patient-reported cost
Direct non-medical costs
Travel costs for visit medical care
Car Number of kilometres Cost manual of Oostenbrink et al. [13] E0.11
Bus/train/taxi Total costs Patient-reported cost
Professional domestic care Hours of help Cost manual of Oostenbrink et al. [13] E18.20
Indirect non-medical costs
Absenteeism from work Number of days Cost manual of Oostenbrink et al. [13] E80.45
Paid household help Total costs Patient reported cost
Informal care Hours of help Cost manual of Oostenbrink et al. [13] E8.83
aSpa treatment¼ 2½ weeks of treatment in a Tunisian Spa resort, including thalassotherapy, supervised exercise and group education.
Spa treatment for fibromyalgia 1455







with respect to sex, age or level of education. Table 2 presents the
demographic characteristics of the patients who completed the
study, and their resource use over the 6 months prior to the start
of the study. The results of these retrospective data indicate no
significant differences between the SPA group and the UC group
in health care consumption, domestic help, employment status
or absenteeism from paid work due to FM (Table 2).
Quality of life
Results of utilities measured by the SF-6D and VAS are shown in
Fig. 1. One and three months after the treatment SPA patients
reported better quality of life, but this effect was not significant
any more after 6 months. Furthermore, utility scores based on
SF-6D were higher than those based on VAS general health.
Differences in time-integrated quality of life (QALYs) between
groups and per period are shown in Table 3. Over the 6-month
follow-up period, quality of life was higher in the SPA group,
measured by the SF-6D as well as the VAS. The between-group
difference in the AUC of the SF-6D was 0.02 (P< 0.05), and 0.04
(P< 0.01) based on the VAS-score. Over the 1 yr follow-up period
no statistically significant between-group differences were found.
Costs
The volumes of health care and non-health care utilization during
the 6-month and 1 yr follow-up period are listed in Tables 4 and 5.
After 6 months of follow-up a small difference in favour of the
SPA group was observed in the number of FM-related visits
to general practitioners and specialists (P< 0.05). After 1 yr, this
difference was only statistically significant for the number of visits
to a specialist (P< 0.05).
The number of hours of domestic care was lower in the SPA
group than in the UC group (5 vs 21 h; P< 0.01) after 6 months
of follow-up. After 1 yr this difference was still statistically
significant (P< 0.05).
In the subgroup of patients with a paid job at study start, no
between-group differences were found over both follow-up
periods with respect to the mean number of sick days due to
FM (Table 5).
TABLE 2. Demographic characteristics and resource use 6 months prior to the study
start of the 128 patients who completed the cost questionnaires: comparison
between the spa treatment (SPA) and usual care (UC) group
SPA (n¼55) UC (n¼73)
Demographic characteristics
Female (%) 95 96
Age (yrs) [median (range)] 48 (22–64) 47 (24–64)
Years since continuous symptoms
onset [median (range)]
10 (2–35) 10 (1–42)
Educational level [median (range)]a 3 (1–6) 3 (1–6)
Employment status employed (%) 44 36
Health-related unemployment (%) 38 36
Other reasons for unemployment (%) 18 28
Paid work [h/week, mean (S.D.)] 23.8 (10.4) 21.3 (11.4)
Absenteeism from paid work
[days, mean (S.D.)]b
30.5 (38.7) 12.8 (22.9)
Resource use over the 6 months prior to study start
General practitioner (GP), visits [mean (S.D.)] 4.0 (4.3) 3.3 (2.7)
Specialists, visits [mean (S.D.)] 1.2 (2.2) 1.7 (2.5)
Paramedical professionals,
visits [mean (S.D.)]
13.3 (15.1) 12.5 (16.1)
Alternative medicine (%) 35 30
Hospitalisation [days, mean (S.D.)] 4.5 (0.7) 5 (5.4)
Professional domestic care
[h/week, mean (S.D.)]
0.5 (1.4) 0.5 (1.3)
Paid household help [h/week, mean (S.D.)] 0.5 (1.1) 0.8 (1.7)
Informal care [h/week, mean (S.D)] 4.5 (7.8) 4.1 (6.1)
aMaximum possible range is 1 (elementary school) – 6 (university).
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FIG. 1. Utilities estimated by the SF-6D and VAS comparing patients of the SPA
treatment (SPA) and usual care (UC) group.
TABLE 3. Quality of life per period comparing patients of the spa treatment (SPA)
and usual care (UC) groupa
Time horizon SPA UC Difference
QALYs, estimated by the SF-6D
0–6 months 0.32 (0.04) 0.30 (0.04) 0.02
0–1 yr 0.61 (0.08) 0.61 (0.07) 0.00
QALYs, estimated by the VAS
0–6 months 0.23 (0.08) 0.19 (0.06) 0.04
0–1 yr 0.42 (0.15) 0.39 (0.12) 0.03
aQALYs indicate quality-adjusted life years: presented as the mean AUC (S.D.) during the study
period.
P<0.05; P< 0.01 for differences between groups (Student’s t-test).
TABLE 4. Volumes of medical and non-medical resource use over the 0–6 month
and 0–1 yr study period comparing patients of the SPA treatment (SPA) and usual
care (UC) groupa
0–6 month 0–1 yr
SPA UC SPA UC
General practitioner
(GP), visits
4.1 (3.8) 3.9 (3.9) 9.4 (7.4) 7.3 (5.6)
Fibromyalgia
(FM)-related
0.8 (1.1) 1.7 (2.1) 4.1 (3.8) 3.9 (3.9)
Specialists, visits 1.7 (3.0) 2.1 (2.5) 3.9 (5.6) 4.6 (4.5)
Fibromyalgia
(FM)-related
0.2 (0.7) 0.6 (1.4) 0.4 (0.9) 1.2 (2.4)
Paramedical
professionals, visits
13.0 (14.0) 11.0 (17.0) 25.7 (27.1) 22.3 (26.8)
Hospitalization (days) 1.7 (7.0) 0.4 (1.8) 2.1 (7.2) 1.0 (2.7)
Professional domestic
care (h)
14.0 (35.0) 11.0 (28.0) 28.0 (71) 20 (56)
Paid household
help (h)
5.0 (16.0) 21.0 (40.0) 13 (35) 46 (83)
Informal care (h) 84.0 (145.0) 71.0 (106.0) 169 (281) 152 (214)
aValues are mean number (S.D.) per patient.
P<0.05; P< 0.01 for differences between groups (Mann–Whitney U-test).
TABLE 5. Comparison of absenteeism from work per period between the
spa treatment (SPA) and usual care (UC) group in a subgroup of 57 patients
with a paid joba
0–6 month 0–1 yr
SPA n¼25 UC n¼29 SPA n¼ 26 UC n¼31
Mean number of
work hours/week
22.2 (11.9) 17.8 (11.3) 21.5 (12.4) 17.4 (11.5)
Absenteeism from
work (days)
11.1 (17.1) 10.7 (25.8) 30.4 (38.9) 32.4 (55.8)
aValues are mean number (S.D.) per patient.
Differences between groups were not statistically significant (Mann–Whitney U-test).
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Mean total costs per patient and treatment group are listed in
Table 6. Mean total costs from societal perspective were E3415
per patient for the SPA group and E2105 for the UC group after 6
months of follow-up. The mean incremental costs were E1311 per
patient (95% CI E369 to 2439), balancing the costs of the
intervention (thalassotherapy including airfare and lodging).
Based on the more realistic cost estimate of E1125 for the spa
treatment programme, the mean incremental costs would be E885
per patient (95% CI E381 to 1790) (data not shown).
Cost–utility
The incremental cost–utility ratio (ICER based on the AUC of the
VAS) after 6 months of follow-up was E1311/0.04¼E32 775
(95% CI 375 000 to 273 000) per QALY gained. The uncertainty
around the ratio was estimated by bootstrapping and is presented
graphically by the cost–utility plane (Fig. 2). This plane shows in
which quadrant of the plane the ‘population’ ratio is to be
expected. The 95% confidence region surrounding this point
estimate spanned all four quadrants of the incremental cost-
effectiveness scatter plot, suggesting inconclusive results. Both the
upper-right (signifying a treatment effect against higher costs)
and upper-left quadrant (no treatment effect against higher costs)
were equally represented within the bootstrapped ratios. In a
negligible percentage of the bootstrapped results the intervention
was cost-saving. The ICER based on the AUC of the SF-6D after
6 months of follow-up was even higher: E1311/0.02¼E65 550
(95% CI 684 000 to 682 000) per QALY gained. Since group
differences at 1 yr were not statistically significant the ICER was
not calculated for this time horizon.
Discussion
The temporary improvement of quality of life due to an adjuvant
course of spa treatment (a combination of thalassotherapy,
exercise and patient education) in patients with FM is associated
with limited incremental costs of E1311 per patient (or E885,
based on the more realistic cost estimate). As the intervention did
not result in a noteworthy decrease in health care consumption
nor in productivity loss, the incremental costs are in fact the added
costs of the spa treatment programme. No conclusions could be
drawn from the incremental cost–utility ratio as the 95% CI had
a high range.
The two QALY measures used in this study led to differing
conclusions about the effectiveness of the intervention. This can
be explained by the fact that conceptual differences exist between
the measurement of utilities by the VAS and SF-6D, as they are
based on different elicitation methods [15]. The VAS general
health is a direct measure of utility representing the individual
valuation of a single health state while the SF-6D is a preference-
based indirect utility measure representing a summary score of six
health states. [11].
TABLE 6. Mean total costs per patient between the SPA treatment (SPA) and usual care (UC) group per study perioda
0–6 months 0–1 yr
SPA (n¼55) UC (n¼73) Difference (95% CI)b SPA (n¼55) UC (n¼73) Difference (95% CI)b
Medical costs mean (S.D.) mean (S.D.) mean (S.D.) mean (S.D.)
Spa treatmentc 1526 (0) 0 (0) 1526 1526 (0) 0 (0) 1526
General practitioner 71 (65) 67 (67) 4 160 (127) 124 (95) 36
Fibromyalgia-related, visits GP 14 (19) 29 (35) 15 71 (65) 67 (67) 4
Specialist 86 (150) 106 (126) 20 198 (279) 232 (226) 34
Fibromyalgia-related, visits Specialist 10 (34) 32 (69) 22 18 (48) 61 (121) 43
Paramedical professionals 241 (269) 211 (325) 30 486 (511) 422 (506) 64
Alternative medicine 12 (30) 45 (106) 33 31 (82) 80 (166) 49
Hospitalization 394 (1,076) 605 (2,518) 211 567 (1326) 827 (2640) 260
Medication 183 (294) 172 (225) 11 383 (557) 335 (391) 48
Fibromyalgia-related, medicationd 55 (99) 51 (98) 4 124 (195) 109 (193) 15
Other medication 128 (269) 121 (206) 7 259 (500) 226 (342) 33
Total medical costs
(including SPA treatment)
2512 (1186) 1207 (2700) 1305 267–2083 3350 (1696) 2020 (2988) 1330 35 to 2390
Direct non-medical costs
Travel costs for visit medical care 16 (23) 21 (43) 5 39 (61) 39 (75) 0
Professional domestic care 248 (643) 194 (518) 54 510 (1288) 367 (1019) 143
Indirect non-medical costs
Absenteeism from work 405 (1019) 331 (1285) 75 1135 (2385) 944 (2342) 191
Paid household help 45 (153) 191 (364) 146 120 (313) 410 (751) 290
Informal care 189 (326) 161 (238) 28 385 (656) 341 (481) 44
Total non-medical costs 903 (1168) 898 (1534) 7 644 to 633 2188 (2629) 2102 (2897) 86 1189 to 1297
Total societal costs
(excluding SPA treatment)
1889 (1714) 2105 3967) 216 1974 to 869 4013 (3333) 4122 (5048) 109 2202 to 1596
Total societal costs
(including SPA treatment)
3415 (1714) 2105 (3967) 1311 369 to 2439 5539 (3333) 4122 (5048) 1417 593 to 3156
aValues are mean (S.D.) costs per patient in Euro.
bDouble-sided bootstrapping.
cSpa treatment¼ 2½ weeks of treatment in a Tunisian Spa resort, including thalassotherapy, supervised exercise and group education.
dFibromyalgia-related medication¼NSAIDs, analgesics and antidepressants; other drugs¼ gastrointestinal drugs, vitamins, homeopathic and other.
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FIG. 2. Cost-utility plane: bootstrap replicates of costs per QALY gained estimated
using the VAS general health after 1 yr of follow-up.
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Our results showed only a few minor differences in health care
consumption. The SPA group reported fewer FM-related visits
to doctors. They also reported less paid household help, possibly
explained by the better physical and mental condition of the
patients [8]. In our study, the overall difference in health-related
costs (spa treatment not included) between both groups was not
significant. This is in line with previous literature. In a study
comparing education and/or social support with no treatment, no
differential changes in health care costs were revealed among
participants in the experimental and control groups [16]. Goossens
et al. [17] reported that the addition of a cognitive component
to an educational intervention led to significantly higher health
care costs and no additional improvement in quality of life as
compared with the educational intervention alone. From these
findings one may assume that the effects of the interventions in
these studies were too small to cause any change in health
care consumption.
Since health resource use was the same in both groups,
sensitivity analysis based on other cost parameters would render
the same net result and was therefore not performed. The only
cost-related parameter that would directly influence cost-
effectiveness is the cost of the spa treatment programme.
In this respect, it should be mentioned that a price estimation
of the spa treatment programme of E1526 per patient is rather
conservative. It would be more realistic to calculate the price of
the spa treatment programme based on 2007 airfares and a 20%
group discount, since insurance companies can obtain package
deals for large numbers of patients. This would result in an
estimated price of E1125 per patient, reducing the incremental
costs from E1311 to E810 per patient. Consequently, the ICER
would be reduced to E810/0.04¼E20 250 per QALY gained.
On the other hand, our study probably slightly underestimated
costs as productivity losses were estimated by the friction costs
approach (FCA). Huscher et al. [18] showed that indirect costs
differ by a factor of 3, based on whether the human capital
approach (HCA) or the FCA is used. However, as no significant
between-group differences in absenteeism from work were found,
it probably has a limited effect on the incremental costs and thus
on the final results.
Among the strong points of our study is its prospective
randomized controlled design as well as a minimal loss to follow-
up. Subjects were no highly selected patients from a tertiary
referral centre, allowing us to generalize the results. Both direct
and indirect costs were included in the analysis. This is important,
since indirect costs may account for up to 70% of total
FM-related costs [6]. We used a randomization-before-consent
design, in which control patients only received information
concerning their part of the protocol but not the spa treatment.
By doing so, we tried to avoid disappointment, which could have
negatively influenced patients’ willingness to participate in the
study or their reporting of subjective outcome. Although the UC
group was thus ‘blinded’ to the intervention, the SPA group could
not be blinded, nor were the observers. Even so, from the way that
costs were assessed we do not expect the lack of blinding to
have significantly influenced our cost-related data.
This is the first study that addresses the cost-effectiveness of spa
treatment in patients with FM. Although other multidisciplinary
treatment programmes were shown to improve the symptoms of
FM [19, 20], evidence of their cost-effectiveness is still lacking [7].
The study by Goossens et al. [17] addressed only the cost-
effectiveness of cognitive behavioural therapy in addition to
patient education, but not the combination of the two [21].
The cost-effectiveness of combined spa-exercise therapy has
been studied in Dutch patients with ankylosing spondylitis [22].
The costs per QALY gained (estimated by the EQ-5D) were
E7465 for spa-exercise therapy in Bad Hofgastein, Austria and
E18 575 for spa-exercise therapy in a Dutch spa resort. Mean total
incremental costs in the intervention groups (E1269 and E1486)
were comparable with the incremental costs in our study (E1417)
and were mainly explained by the cost of treatment. Furthermore,
no important reduction in other health-related costs occurred.
Given the similar mean incremental costs per patient in both
studies, the higher cost–utility ratio in the present study was due
to smaller effects on utilities. However, a direct comparison
between studies is difficult, since different measures for utilities
were used. It has been shown that the method employed to
determine the utility of health states has major effects on the
outcome of cost–utility studies [15]. According to Lamers et al.
[23] the use of EQ-5D resulted in larger health gains and
consequent lower cost–utility ratios although this was studied in
patients with mood or anxiety disorders.
Our study aimed at providing information on costs and effects
of combined spa treatment in FM. The next question will be
whether the incremental costs of this treatment are acceptable.
Society should consider whether a temporary improvement in
quality of life is worth the incremental costs, given the fact that
only a few, if any, effective treatments are available for patients
with FM.
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